Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
28 févr. 2024 07h00 HE
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
08 févr. 2024 07h00 HE
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
08 janv. 2024 07h00 HE
|
Foghorn Therapeutics, Inc.
- FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; preclinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs)...
Foghorn Therapeutics Announces CFO Departure
03 janv. 2024 16h05 HE
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
01 déc. 2023 07h00 HE
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
02 nov. 2023 07h00 HE
|
Foghorn Therapeutics, Inc.
First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024Transitioned the BRM Selective inhibitor program to Loxo@LillyPresented preclinical data demonstrating...
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
24 oct. 2023 08h00 HE
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
13 oct. 2023 08h00 HE
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
04 oct. 2023 08h00 HE
|
Foghorn Therapeutics, Inc.
Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor typesFHD-286, a potent, selective inhibitor of BRG1 and BRM, shows potential as a broad-based differentiation...
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
05 sept. 2023 08h00 HE
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...